Theranexus
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-13 18:00 |
Regulatory News Service
THERANEXUS AND BEYOND BATTEN DISEASE FOUNDATION ANNOUNCE STRONG POSITIVE REAL-W…
|
English | 391.8 KB | |
| 2025-05-13 18:00 |
Regulatory News Service
THERANEXUS ET LA FONDATION BEYOND BATTEN DISEASE ANNONCENT DES DONNÉES EN VIE R…
|
French | 352.9 KB | |
| 2025-04-29 19:05 |
Registration Form
URD 2024
|
French | 10.6 MB | |
| 2025-04-29 19:00 |
Earnings Release
THERANEXUS PUBLISHES ITS 2024 FULL-YEAR RESULTS, PRESENTS ITS PROGRESS REPORT A…
|
English | 336.5 KB | |
| 2025-04-29 19:00 |
Earnings Release
THERANEXUS PUBLIE SES RÉSULTATS ANNUELS 2024, FAIT LE POINT SUR SES ACTIVITÉS E…
|
French | 297.3 KB | |
| 2025-03-06 18:00 |
Capital/Financing Update
MODIFICATION DU CONTRAT DE LIQUIDITÉ CONFIÉ À PORTZAMPARC
|
French | 272.5 KB | |
| 2025-01-23 18:15 |
Inside Information Statement
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025
|
English | 262.8 KB | |
| 2025-01-23 18:00 |
Inside Information Statement
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2025
|
French | 254.5 KB | |
| 2025-01-16 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total de droits de vote et d'actions c…
|
French | 168.8 KB | |
| 2025-01-09 18:00 |
Regulatory News Service
THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS
|
English | 179.9 KB | |
| 2025-01-09 18:00 |
Regulatory News Service
THERANEXUS ANNONCE LA PUBLICATION DE SA LETTRE AUX ACTIONNAIRES
|
French | 181.7 KB | |
| 2024-12-17 18:15 |
Inside Information Statement
THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON
|
English | 212.3 KB | |
| 2024-12-17 18:15 |
Inside Information Statement
THERANEXUS FAIT UN POINT SUR SA POSITION DE TRÉSORERIE ET SON HORIZON DE FINANC…
|
French | 230.9 KB | |
| 2024-12-17 18:00 |
Regulatory News Service
THERANEXUS ET EXELTIS (INSUD PHARMA) ANNONCENT UN ACCORD DE LICENCE POUR LA COM…
|
French | 178.0 KB | |
| 2024-12-17 18:00 |
Regulatory News Service
THERANEXUS AND EXELTIS (INSUD PHARMA) ANNOUNCE LICENSING AGREEMENT TO COMMERCIA…
|
English | 177.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |